SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 unusual trades. Delving into the details, we ...

Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its ...

Barclays analyst Peter Lawson maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report) yesterday and set a price target of ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for ...

HC Wainwright reiterated their buy rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX – Free Report) in a report published on Friday,Benzinga reports. They currently have a $74.00 price ...

Guggenheim analyst Michael Schmidt maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) yesterday and set a price target ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) saw some unusual options trading on Thursday. Traders acquired 13,068 call options on the stock. This is an increase of 223% compared to ...